

Reverse Payments After *Actavis*: Fifteen Cases to Follow

Published by Bloomberg BNA

July 11, 2014

A year after the Supreme Court's ruling in *FTC v. Actavis, Inc.*, this article discusses fifteen ongoing cases that implicate "pay for delay" settlements in pharmaceutical patent litigation. It highlights key issues in dispute in each of these cases as the courts apply the "rule of reason" in novel and complex contexts.

CONTACTS

For more information, contact your Katten attorney or any of the following attorneys.



Brian Sodikoff

+1.312.902.5462

brian.sodikoff@katten.com

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2026 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at [katten.com/disclaimer](https://www.katten.com/disclaimer).